Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADO-TRASTUZUMAB EMTANSINE Cause Optic neuritis? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Optic neuritis have been filed in association with ADO-TRASTUZUMAB EMTANSINE. This represents 0.1% of all adverse event reports for ADO-TRASTUZUMAB EMTANSINE.

6
Reports of Optic neuritis with ADO-TRASTUZUMAB EMTANSINE
0.1%
of all ADO-TRASTUZUMAB EMTANSINE reports
1
Deaths
1
Hospitalizations

How Dangerous Is Optic neuritis From ADO-TRASTUZUMAB EMTANSINE?

Of the 6 reports, 1 (16.7%) resulted in death, 1 (16.7%) required hospitalization, and 1 (16.7%) were considered life-threatening.

Is Optic neuritis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADO-TRASTUZUMAB EMTANSINE. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does ADO-TRASTUZUMAB EMTANSINE Cause?

Nausea (780) Fatigue (774) Disease progression (750) Diarrhoea (654) Off label use (630) Thrombocytopenia (519) Death (509) Neuropathy peripheral (506) Headache (465) Platelet count decreased (453)

What Other Drugs Cause Optic neuritis?

FINGOLIMOD (619) INTERFERON BETA-1A (422) DIMETHYL (373) NATALIZUMAB (272) OCRELIZUMAB (236) ADALIMUMAB (229) TERIFLUNOMIDE (225) GLATIRAMER (196) OFATUMUMAB (185) RITUXIMAB (164)

Which ADO-TRASTUZUMAB EMTANSINE Alternatives Have Lower Optic neuritis Risk?

ADO-TRASTUZUMAB EMTANSINE vs ADRIAMYCIN ADO-TRASTUZUMAB EMTANSINE vs ADUCANUMAB ADO-TRASTUZUMAB EMTANSINE vs ADUCANUMAB-AVWA ADO-TRASTUZUMAB EMTANSINE vs ADVAIR ADO-TRASTUZUMAB EMTANSINE vs ADVAIR HFA

Related Pages

ADO-TRASTUZUMAB EMTANSINE Full Profile All Optic neuritis Reports All Drugs Causing Optic neuritis ADO-TRASTUZUMAB EMTANSINE Demographics